Table 1 Characteristics of the studies
Author | Year | Type | Sample size | Age, median (range) | Gender (male/female) | Tx 1 | Tx 2 | De novo,n | Secondary, n |
|---|---|---|---|---|---|---|---|---|---|
Burnett, A. K | 2013 | RCT | 495 | 75 (54–90) | 300/195 | LDAC | LDAC + GO | 325 | 106 |
Kantarjian, H. M | 2013 | RCT | 77 | 76 (61–85) | 45/32 | LDAC | Barasertib | 35 | 42 |
Döhner, H | 2014 | RCT | 87 | 75.5 (57–87) | 48/39 | LDAC | LDAC + Volasertib | 60 | 27 |
Thomas, X. G | 2014 | RCT | 485 | 73 (64–91) | 288/197 | LDAC | Dec | 314 | 171 |
Burnett, A. K | 2015 | RCT | 143 | 75 (54–88) | 94/49 | LDAC | Sapacitabine | 85 | 37 |
Dennis, M | 2015 | RCT | 104 | 75 (60–89) | 67/37 | LDAC | Vosaroxin | 65 | 31 |
Dennis, M.2 | 2015 | RCT | 104 | 75 (60–91) | 69/35 | LDAC | LDAC + Vosaroxin | 65 | 27 |
Jacob, L. A | 2015 | Cohort study | 30 | 63.5 | 24/6 | Decitabine | LDAC | 28 | 2 |
Roboz, G. J | 2018 | RCT | 165 | 72.4 (60.5–92.3) | 113/50 | Decitabine | Dec + Bortezomib | 110 | 18 |
Cortes, J. E | 2019 | RCT | 132 | 76 (58–92) | 95/37 | LDAC | LDAC + Glasdegib | * | * |
DiNardo, C. D | 2020 | RCT | 431 | 76 (49–91) | 259/172 | Azacitidine | Aza + Venetoclax | 324 | 107 |
Huls, G | 2020 | RCT | 144 | 75.5 (66–89) | 89/55 | Decitabine | Dec + Ibrutinib | 93 | 28 |
Wei, A. H | 2020 | RCT | 211 | 76 (36–93) | 117/34 | LDAC | LDAC + Venetoclax | 130 | 81 |
Pepe,S | 2020 | Cohort study | 110 | 75 (58–89) | 74/36 | Decitabine | Aza | 62 | 44 |
Dohner, H | 2021 | RCT | 666 | 75 (65–93) | 376/290 | LDAC | LDAC + Volasertib | 344 | 322 |
Heuser, M | 2021 | RCT | 116 | 76.7 (58–92) | 82/34 | LDAC | LDAC + Glasdegib | 56 | 60 |
Hu, Y | 2021 | RCT | 15 | 72 (61–86) | N6/9 | LDAC | LDAC + Venetoclax | 14 | 1 |
Montesinos, P | 2021 | RCT | 316 | 75 (65–92) | 171/145 | Decitabine | Dec + Talacotuzumab | 213 | 103 |
Berdel, Andrew F | 2022 | RCT | 30 | 76 (60–84) | 15/15 | LDAC | LDAC + Nintedanib | 7 | 9 |
Wang, E. S | 2022 | RCT | 123 | 77 (59–90) | 70/53 | Azacitidine | Aza + Gilteritinib | * | * |
Wang, W | 2022 | RCT | 20 | 70.3 (60–83) | 11/9 | Azacitidine | Aza + Venetoclax | * | * |
Yamamoto, K | 2022 | RCT | 37 | 77.3 (67–86) | 23/14 | Azacitidine | Aza + Venetoclax | 30 | 7 |
Zeidan, A. M | 2022 | RCT | 129 | 75.5 (65–89) | 71/58 | Azacitidine | Aza + Durvalumab | 54 | 75 |
Laloi,L | 2023 | Cohort study | 111 | 62 (14–83) | NR | LDAC + Venetoclax | Aza + Venetoclax | 37 | 57 |
Petit,C | 2024 | Cohort study | 175 | 66 (55–71.5) | 99/76 | Azacitidine | Aza + Venetoclax | 92 | 83 |
Baba,Y | 2024 | Cohort study | 33 | 78.7 (58–88) | N8/25 | Azacitidine | Aza + Venetoclax | 17 | 16 |
Pratz,K.W | 2024 | RCT | 431 | 76 (49–90) | 259/172 | Azacitidine | Aza + Venetoclax | 324 | 107 |